NOVARTIS AG
Novartis is a pharmaceutical company headquartered in Basel, Switzerland. It researches, develops, manufactures, markets and sells medicines, with core therapeutic areas in cardiovascular, renal and metabolic diseases, immunology, neuroscience and oncology. It generally sells prescription drugs to wholesalers, retailers, health systems, government agencies and other healthcare providers. It also generates sales from contract manufacturing. Its products include Entresto for heart failure, Cosentyx for immunological diseases, Kisqali for breast cancer, Kesimpta for relapsing multiple sclerosis and Pluvicto for prostate cancer. Novartis operates through Biomedical Research, Development, Operations, and US and International commercial units. Its products are sold in approximately 120 countries.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $NVS in the last 30 days.
See all $NVS insider activity →A Mumbai tax tribunal ruled that Novartis's sale of Indian pharmaceutical trademarks was an outright transfer, not a royalty arrangement, involving 4.33 billion rupees ($46.06 million). The decision clarifies the distinction between trademark transfers and licensing.
South Korea approved Novartis' Banrapia (atrasentan) for IgA nephropathy (IgAN), a kidney disease. The drug, first in Korea for this class, targets a separate biological pathway. Approval came via the GIFT fast-track program. IgAN is prevalent in Korea, with Banrapia offering an add-on treatment. Clinical trials showed significant proteinuria reduction, but long-term kidney function benefits are still under study.
The FDA approved a labeling supplement for Novartis's Lamprene (clofazimine) on 11/03/2026. The change's details were not disclosed, and both strengths of the drug are discontinued, limiting sales impact.
Over the past 7 days, AlphAI's AI scored 29 news stories mentioning NVS (NOVARTIS AG). Coverage has skewed bearish: 7 bullish, 2 neutral, and 20 bearish.
Recent NVS coverage spans financial news, regulation and technology.
The ruling may increase Novartis' tax liability and affect future IP sale structuring.
The approval opens a new market for Novartis, likely driving short-term share upside pending reimbursement.
The filing provides no new commercial benefit and signals discontinued products, likely weighing on the stock.
Neutral to slightly negative impact as the company sheds a non‑core partnership.
Positive phase 3 data may boost investor confidence in Novartis' autoimmune pipeline.
AlphAI scores every news story that mentions NVS with an AI model for sentiment and relevance, and aggregates insider trades from NOVARTIS AG's SEC EDGAR Form 4 filings. Figures refresh continuously.
A Mumbai tax tribunal ruled that Novartis's sale of Indian pharmaceutical trademarks was an outright transfer, not a royalty arrangement, involving 4.33 billion rupees ($46.06 million). The decision clarifies the distinction between trademark transfers and licensing.
South Korea approved Novartis' Banrapia (atrasentan) for IgA nephropathy (IgAN), a kidney disease. The drug, first in Korea for this class, targets a separate biological pathway. Approval came via the GIFT fast-track program. IgAN is prevalent in Korea, with Banrapia offering an add-on treatment. Clinical trials showed significant proteinuria reduction, but long-term kidney function benefits are still under study.
The FDA approved a labeling supplement for Novartis's Lamprene (clofazimine) on 11/03/2026. The change's details were not disclosed, and both strengths of the drug are discontinued, limiting sales impact.
Novartis terminated its collaboration with BioArctic on a brain-delivery technology, according to a Nov. 2 announcement. BioArctic's shares dropped over 7% in early trading. The deal, worth up to $802M, was specific to a Novartis program and did not affect BioArctic's other partnerships, including one with Eli Lilly. BioArctic will recognize remaining unrecognized upfront payment as revenue in 2026. BioArctic reported SEK 1,990M in cash and short-term investments at the end of June.
Novartis' ianalumab showed greater reductions in Sjögren’s disease activity vs. placebo at 48 weeks in two trials, per NEJM. The 300 mg monthly dose improved ESSDAI scores, but no significant differences in symptom scores. Injection reactions were more common with ianalumab.
Illumina, Tempus AI, and Novartis raised FY26 guidance. Illumina reported $1.13B Q3 revenue, +4.2% YoY, and adjusted EPS of $1.44, +7% YoY. Tempus AI saw 23% YoY revenue growth to $411.5M. Novartis improved profit outlook to flat-to-low-single-digit growth.
Novartis' experimental heart drug, pelacarsen, failed to reduce heart attack and stroke risk in a large trial, despite lowering Lp(a) levels by 80%. Doctors and investors await detailed results. Other drugmakers, like Amgen and Eli Lilly, are developing similar drugs. Novartis' stock dropped 16% following the news. The trial's outcome may impact future Lp(a)-targeting drug development.
Novartis stock slipped after Deutsche Bank downgraded it to 'sell' and reduced its price target to 115 Swiss francs. Samsung Biologics acquired 97.98% of PolyPeptide Group shares and plans to squeeze out the rest, causing PolyPeptide's shares to fall 1.55%.
Deutsche Bank downgraded Novartis (NOVN) to 'sell' from 'hold', cutting its price target to CHF115 from CHF120. The bank cited the stock's recovery from failed drug trials and a 'somewhat mixed' third quarter. Novartis reported Q3 core EPS of $2.46, beating estimates, but revenue missed. The stock trades at a P/E of 31.11, 6% below its 52-week high.
Deutsche Bank downgraded Novartis (NYSE: NVS) to Sell from Hold, lowering its price target to CHF115.00 from CHF120.00, citing mixed Q3 results and high valuation. The stock has risen post-earnings, trading near its 52-week high with a P/E ratio of 31.11. Novartis reported Q3 core EPS of $2.46, beating estimates, but revenue was slightly below expectations at $14.52 billion. The company raised its profit outlook despite a significant impairment charge.
